KISSEI PHARMACEUTICAL CO.,LTD. Logo

KISSEI PHARMACEUTICAL CO.,LTD.

Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.

4547 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
松本市芳野19番48号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kissei Pharmaceutical Co., Ltd. is a research-driven pharmaceutical company engaged in the development, manufacturing, and commercialization of innovative medicines. The company strategically focuses its research and development efforts on specific therapeutic areas, including urology, renal diseases and dialysis, and rare or intractable diseases. Its business model integrates in-house drug discovery with strategic partnerships, such as in-licensing and out-licensing agreements, to build a robust product pipeline. Kissei's portfolio comprises both specialty and generic drugs, aiming to address unmet medical needs and contribute to the health of people globally.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for KISSEI PHARMACEUTICAL CO.,LTD. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 06:00
Regulatory News Service
臨時報告書
Japanese 23.3 KB
2025-06-24 06:01
Regulatory News Service
確認書
Japanese 9.0 KB
2025-06-24 06:01
Regulatory News Service
内部統制報告書-第80期(2024/04/01-2025/03/31)
Japanese 25.5 KB
2025-06-24 06:00
Annual Report
有価証券報告書-第80期(2024/04/01-2025/03/31)
Japanese 1.5 MB
2025-06-11 06:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 22.6 KB
2024-12-27 08:00
Major Shareholding Notification
大量保有報告書
Japanese 38.5 KB
2024-12-13 05:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-11-13 05:01
Regulatory News Service
確認書
Japanese 9.0 KB
2024-11-13 05:00
Interim Report
半期報告書-第80期(2024/04/01-2025/03/31)
Japanese 240.5 KB
2024-06-28 06:00
Regulatory News Service
臨時報告書
Japanese 29.4 KB
2024-06-25 06:01
Regulatory News Service
内部統制報告書-第79期(2023/04/01-2024/03/31)
Japanese 23.8 KB
2024-06-25 06:00
Regulatory News Service
確認書
Japanese 9.0 KB
2024-06-25 06:00
Annual Report
有価証券報告書-第79期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2024-02-13 05:00
Regulatory News Service
確認書
Japanese 9.0 KB
2024-02-13 05:00
Quarterly Report
四半期報告書-第79期第3四半期(2023/10/01-2023/12/31)
Japanese 193.7 KB

Automate Your Workflow. Get a real-time feed of all KISSEI PHARMACEUTICAL CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for KISSEI PHARMACEUTICAL CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pharmocann Global Ltd. Logo
Develops pharma-grade medical cannabis products like oils, ointments, tablets, and cosmetics.
Israel PMCN-M
Pherecydes Pharma Logo
Develops precision phage therapy to treat resistant bacterial infections.
France ALPHE
Philogen Logo
Developing targeted biopharmaceuticals for oncology using proprietary ligand-based delivery.
Italy PHIL
Photocure ASA Logo
Develops photodynamic pharmaceuticals and devices to enhance bladder cancer detection for urologists.
Norway PHO
Pierrel Logo
Global pharma company specializing in dental anesthetics and contract manufacturing services.
Italy PRL
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Psych Capital Plc Logo
A life sciences firm developing psilocybin treatments for anorexia and mental health conditions.
United Kingdom PSY
Pure Biologics S.A. Logo
Develops novel antibody & aptamer drugs for immuno-oncology and autoimmune diseases.
Poland PUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.